-
HitGen Inc. Partners with Ablink Biotech to Develop Antibody-Oligonucleotide Conjugates
•
China-based HitGen Inc. (SHA: 688222) has entered into a partnership with compatriot firm Ablink Biotech to integrate their world-leading trillion-level DNA-Encoded Libraries (DELs), a comprehensive small nucleic acid drug discovery and production platform, and a 300 billion-level biopharmaceutical molecule library. The collaboration aims to provide research and development services for…
-
HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups
•
China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science and biotechnology startup incubation platform; BioLabs, an international network of membership-based shared laboratory and office spaces; and MBC BioLabs, a provider of shared laboratory facilities. Recognized as a leader in DNA-encoded library (DEL) technology and…
-
HitGen Secures CDE Approval for Lipisense IND Filing, Advancing Development for Dyslipidemia Treatment
•
HitGen Inc., (SHA: 688222) a China-based pharmaceutical company, has announced that the Investigational New Drug (IND) filing for its Lipisense (A24110He for injection) has received approval from China’s Center for Drug Evaluation (CDE). Lipisense, an innovative antisense oligonucleotide (ASO) drug originally developed by Swiss firm Lipigon Pharmaceuticals AB, is designed…
-
HitGen’s Vernalis Partners with Hox Therapeutics to Develop Novel Cancer Inhibitors
•
HitGen Inc. (SHA: 688222), based in China, announced that its wholly owned subsidiary Vernalis (R&D) Ltd will collaborate with Hox Therapeutics Ltd, a private biotech firm dedicated to developing highly targeted cancer therapies, to create inhibitors aimed at undisclosed targets. Vernalis will leverage its advanced protein science capabilities and Hit…
-
HitGen Inc. and Bostal Drug Delivery Form Strategic Partnership to Advance Nucleic Acid Drug Development
•
HitGen Inc. (SHA: 688222), a China-based company, has announced a strategic partnership with Bostal Drug Delivery Co., Ltd through its subsidiary, Sichuan Xiandong Pharmaceutical Co., Ltd. This alliance is aimed at the research and development (R&D) and manufacturing of nucleic acid drugs, marking a significant step forward in the field…
-
Panlin Capital Raises Second Fund Focused on Biopharmaceutical Innovation
•
Panlin Capital has announced the successful closing of its second venture capital fund, the Hangzhou Panlin Xukang Fund, which will concentrate on innovative biopharmaceuticals, medical devices, and biotechnology sectors. This marks the first fund established by Panlin Capital in Hangzhou and the second venture capital fund raised by the firm…
-
Canada’s SGC Partners with HitGen to Enhance Drug Discovery Using DEL Technology
•
The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen Inc. (SHA: 688222). This collaboration will leverage HitGen’s DNA-encoded library (DEL) technology platform to screen under-represented targets identified by SGC. The resulting screening datasets will be made available on a publicly accessible portal, enabling global…
